Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
about
Does HAART efficacy translate to effectiveness? Evidence for a trial effectLow dose versus high dose stavudine for treating people with HIV infectionAntiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapyIn vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsPersistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case reportDual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsPerspectives on menopause and women with HIVWhen to start antiretroviral therapy: as soon as possibleHIV: inflammation and boneHIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsMultidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolitesTenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trialEvolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatmentIncreasing rates of obesity among HIV-infected persons during the HIV epidemicBone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San FranciscoEnrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, ThailandResistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysisIncidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort studyCost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringThe effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicityStanding genetic variation and the evolution of drug resistance in HIVRates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovirReasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort AnalysisThe Global Health Impact Index: Promoting Global HealthChanges in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudineComparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trialPilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimenSide effects of HIV therapyBone health in HIV and hepatitis B or C infectionsGetting to 90-90-90 in paediatric HIV: What is needed?Pseudogout Associated Hip Pain in a Patient with HIV Infection.Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance.Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection.Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation.Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.
P2860
Q21135313-19A636F7-0799-4C4D-B4E7-082B64DF740DQ24186488-EF8AEE01-CE1F-4ED8-930D-298BC800956BQ24672068-812C68D4-8572-4BD2-9114-DAABA734465CQ24674939-B3341E4C-B720-4D78-A605-722060BFA9A4Q24814430-ACD6F4A9-3FB3-4ED9-8EB7-3DCF766AC4DCQ26768591-E1FB8C97-58C7-479A-8900-89FD1EE5EFD8Q26772852-8692AB21-DD55-4D58-B97A-31AD76EA1983Q27006767-6B0591FF-AAB9-441C-AFBC-E1BBA3121801Q27010898-D014DBDC-5C5C-4FC0-B23D-EBC9977AEB74Q28088839-F711B225-CAEB-4FBE-87DC-D8DACC4B6810Q28289901-4D10DBAD-5F0A-4038-9420-70625AC8B966Q28469218-BBF98447-712F-4DE7-847B-3C2697093E2DQ28471623-F362D7D7-7AF4-4B0A-8C92-C34EF7AC4738Q28473706-BCDB48EB-F437-4341-AEFF-B48A4D6F6167Q28476730-02E34D13-921C-4A48-85AF-FC33F9EAB409Q28477258-9D68A4E4-D77D-4F72-9157-54390C171510Q28478121-1BBFD3F6-933F-4ECB-AD5F-029B59F3AAD4Q28480421-9F1CC34E-390E-4C73-B615-BB4C25851063Q28482138-0D5FDB86-8B84-4114-B41D-1C3F9CC345D8Q28483688-7CE7FC99-B43B-4007-9B3E-A01487BE4BADQ28484153-BF896E63-86C4-4A35-8A3C-5554800BA9B2Q28533242-F47D4FEE-117A-4FFA-AA39-F2DFD635FB13Q28546795-71611B15-3E16-4D94-9F8E-171138A526EAQ28551476-BCE4A627-D578-43D7-9122-30A38AD73B5BQ28728374-D031CF61-9AB3-4A7F-9EC4-DEF0AB880AF5Q28730855-807252FC-58E9-4A43-83B6-0C689B37BCF2Q28741214-F34D5439-3F6C-47D8-975F-581D68D113F9Q29394405-E278A6D2-0527-4AAB-B6FD-F4047BF19A79Q30238946-C02E50D5-BB4F-46F6-B59E-7A06E26A5E47Q30385352-22FD77FD-33CA-4C23-BFA4-3AD910AF2355Q30398286-8054D944-354A-4667-BCDC-CEFCDE44AB8AQ30983924-9DF7EAA2-1260-4805-93C7-81ABF9F5E81CQ31028855-A4683B17-2AB7-42DC-8E64-DF766C0C7986Q31050092-61695F04-125C-4BA9-8477-D72ECA18EDD3Q31143771-938EF112-D139-45D6-AACE-803E6DEDA1B4Q33258171-DD0B383A-D3FB-4175-8AF5-66D351C7E4F1Q33265482-6065C2E4-061A-439C-94BB-EB8B560F4495Q33325623-D566AAC4-BF92-4E14-AB55-0F738393CFF5Q33455840-CB0A6253-668A-449B-B708-BB06D64B5545Q33532361-A2045710-44E8-4225-B972-873B5F99C943
P2860
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Efficacy and safety of tenofov ...... ts: a 3-year randomized trial.
@en
Efficacy and safety of tenofov ...... ts: a 3-year randomized trial.
@nl
type
label
Efficacy and safety of tenofov ...... ts: a 3-year randomized trial.
@en
Efficacy and safety of tenofov ...... ts: a 3-year randomized trial.
@nl
prefLabel
Efficacy and safety of tenofov ...... ts: a 3-year randomized trial.
@en
Efficacy and safety of tenofov ...... ts: a 3-year randomized trial.
@nl
P2093
P356
P1476
Efficacy and safety of tenofov ...... ts: a 3-year randomized trial.
@en
P2093
903 Study Group
Andrew K Cheng
Anton L Pozniak
Dion F Coakley
Edwin DeJesus
Jamal M A H Suleiman
Joel E Gallant
John J Toole
Michael D Miller
P304
P356
10.1001/JAMA.292.2.191
P407
P577
2004-07-01T00:00:00Z